Jubilant Pharmova passes all AGM resolutions, approves ₹5 dividend
- Shareholders approved all resolutions at the 48th AGM, including a ₹5 per share dividend
- FY26 consolidated revenue grew 14% to ₹83 billion; EBITDA rose 8% to ₹13 billion
- Q1FY27 revenue increased 17% to ₹22 billion, though margins faced temporary headwinds
- CDMO Sterile Injectables revenue surged 38%, driven by Line 3 launch at Spokane
- Directors Hari Shanker Bhartia and Arjun Shanker Bhartia were reappointed by rotation
*this image is generated using AI for illustrative purposes only.
Jubilant Pharmova Limited shareholders approved all resolutions at the 48th Annual General Meeting held on August 26, 2026. The assembly endorsed a dividend of ₹5 per equity share and reappointed directors Hari Shanker Bhartia and Arjun Shanker Bhartia.
The meeting, conducted via video conferencing, saw participation from 86 members representing over 70 million shares. Chairman Shyam Sunder Bhartia presided over the proceedings, highlighting the company's financial performance and strategic progress toward Vision 2030.
Financial Performance in FY26
Consolidated revenue from operations rose 14% to ₹83 billion in FY26. EBITDA increased 8% to ₹13 billion, while normalised profit after tax grew 7% to ₹4 billion. The net debt-to-EBITDA ratio moved from 1.1x to 1.3x, reflecting growth-oriented capital expenditure.
| Metric | FY26 Value | YoY Change |
|---|---|---|
| Revenue | ₹83 billion | +14% |
| EBITDA | ₹13 billion | +8% |
| Normalised PAT | ₹4 billion | +7% |
Segment Highlights
The Radiopharmaceuticals business maintained leadership in SPECT imaging and expanded its Ruby-Fill® installed base, delivering EBITDA margins of 41%. The Allergy Immunotherapy segment reported EBITDA margins of 35%.
CDMO Sterile Injectables revenue surged 38%, driven by the launch of Line 3 at the Spokane facility. CRDMO revenue grew 15%, while the Generics business saw a significant profitability improvement with EBITDA rising 250% despite a 13% revenue increase.
Q1FY27 Outlook
Revenue for the first quarter of FY27 increased 17% year-on-year to approximately ₹22 billion. EBITDA stood at ₹2.7 billion. Management noted that profitability was impacted by temporary unavailability of high-margin SPECT products and remediation costs at the Montreal facility. Production is expected to normalise in the second half of FY27.
What the Numbers Show
The divergence between CDMO Sterile Injectables revenue growth (38%) and consolidated EBITDA growth (8%) indicates that while top-line expansion was robust, margin accretion from new capacity ramp-ups like Line 3 may still be in early stages or offset by costs elsewhere. Conversely, the Generics business demonstrated strong operating leverage, with EBITDA growing 250% against only 13% revenue growth, suggesting successful cost optimization or product mix shifts.
Voting Results
All ordinary resolutions were passed with requisite majorities. Promoter group voting support remained near-universal across all agenda items. Public institutional dissent was minimal, with less than 2% negative votes on director reappointments.
Historical Stock Returns for Jubilant Pharmova
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.71% | +0.34% | -3.14% | +4.56% | -11.47% | +36.56% |
How will the normalization of SPECT product availability and resolution of Montreal facility issues in H2 FY27 impact Jubilant Pharmova's EBITDA margins compared to Q1?
What is the expected timeline for Line 3 at the Spokane facility to reach full capacity utilization and contribute meaningfully to consolidated EBITDA growth?
Given the rise in net debt-to-EBITDA ratio to 1.3x, what specific capital expenditure projects are driving this leverage, and how does management plan to deleverage in the medium term?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
